Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

RA, Larson; BJ, Druker; F, Guilhot; SG, O'Brien; GJ, Riviere; T, Krahnke; I, Gathmann; Y, Wang

doi:10.1182/blood-2007-10-116475

Public

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

Shared by NobleBlocks on Feb 6, 2008 • 12:00 AM UTC

Authors:

Larson RA

Druker BJ

Guilhot F

Abstract

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of imatinib trough plasma concentrations (C(mins)) with clinical responses, event-free survival (EFS), and adverse events (AEs). Trough level plasma samples were obtained on...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!